In late April, the Parkinson and Movement Disorder (PMD) Alliance hosted a webinar on the different drug classes for Parkinson’s disease (PD) medication. The speaker was movement disorder specialist Dr. Yasser Torres-Yaghi.
… Full Story>Impulse Control Disorders (in Parkinson’s) – Webinar notes
In mid-May, the Parkinson’s and Movement Disorder (PMD) Alliance hosted movement disorder specialist Dr. Joseph Friedman to speak on impulse control disorders in Parkinson’s disease (PD). Impulse control disorders (ICD) is a term used to describe the numerous compulsory disorders associated with dopamine agonist drugs, primarily in PD but also in other disorders. Examples are gambling, hypersexuality, shopping, etc.
… Full Story>Dr. Gilbert Hosts: Parkinson’s Disease Research at the NIH – Webinar notes
In May, the American Parkinson Disease Association (APDA) hosted a webinar on Parkinson’s disease research at the National Institute of Health (NIH). The speaker was Dr. Walter Koroshetz, director of the NIH’s National Institute of Neurological Disorders and Strokes (NINDS). Dr. Koroshetz reviewed what the $223 million investment into Parkinson’s Disease (PD) research funds.
… Full Story>Register now for APDA’s “Dr. Gilbert Hosts: The Environment and Parkinson’s Disease” Webinar on Wednesday, June 16
Register now for the next episode of “Dr. Gilbert Hosts” where APDA’s Chief Scientific Officer, Dr. Rebecca Gilbert, speaks with Dr. Carlie Tanner about the effects of the environment on the risk of developing PD. Dr. Tanner is the Associate Director at the Parkinson’s Disease Research Education and Clinical Center at the San Francisco VA. The webinar is scheduled for Wednesday, June 16, 9am PT.
… Full Story>“Update on (Parkinson’s) Disease Modifying Therapies” – Webinar notes
According to the speaker, there are three different kinds of therapies – symptomatic, disease-modifying, and neuroprotective. Currently, all approved therapies are only for symptomatic treatment; these therapies help improve symptoms – appearance and impact – without affecting the underlying cause of disease. Neuroprotective therapies aim to protect neurons. These therapies can’t be done by looking at a person clinically; neurons themselves must be studied.
… Full Story>- « Previous Page
- 1
- …
- 45
- 46
- 47
- 48
- 49
- …
- 159
- Next Page »